



Duravest to Present at ARCH Investment Conference on May 18

CHICAGO, IL-(MARKET WIRE)-May 15, 2006-Duravest, Inc. (OTC BB: DUVT) (XETRA: DUV), a unique company that strategically acquires and accelerates the development of next generation convergent medical technology firms, today announces that Ogan Gurel, MD MPhil, President and CEO, will present at the upcoming Arch Investment Conference on May 18 at 9:00 am at the Hotel Plaza Athenee in New York. Duravest was selected by Arch as one of only six companies to present to an exclusive audience of fund managers and analysts as well as investment bankers, brokers, media, and other members of the investment community.

The Conference brings together investors in high-growth companies and small cap firms with compelling business models. Dr. Gurel will present Duravest's exciting corporate strategy and highlight the latest developments taking place at both the corporate and subsidiary level. The details of the presentation are as follows:

Date: Thursday, May 18, 2006

Time: 9:00 am

Place: Hotel Plaza Athenee

37 East 64th Street (between Park and Madison Avenues)

New York City

Website: <http://www.archconferences.com/ArchConferenceSchedule.htm>

"We are delighted to have the opportunity to address this important group of investors. With over 1200 investors participating, we look forward to communicating the latest developments with respect to Duravest's cutting edge business strategy, as well as the exciting progress being made with our two current subsidiaries, BMTS and Estracure," said Dr. Gurel on Monday.

About Arch Investment Conferences, Inc.

Arch Investment Conferences, Inc. is a premier sponsor of investment conferences reaching the institutional investor community. Arch's audience is more than 1200 - primarily institutional - investors. Arch is dedicated to bridging the gap between companies and fund managers, analysts, investment bankers, brokers and the rest of the financial community. Arch works directly with companies as well as with investor relations and public relations firms, fund managers, analysts, and other members of the investment community to showcase compelling investment ideas and provide a forum for exciting companies to showcase their stories.

Duravest, Inc.

Duravest, Inc. (OTC BB: DUVT) (XETRA: DUV) is a publicly traded holding company that initiates and develops strategic investments in next-generation convergent medical technologies. Duravest currently has two subsidiaries: Estracure, Inc. and Bio-Magnetic Therapy Systems, GmbH (BMTS). Estracure is developing a next-generation 17-beta-estradiol based coronary stent and the company is poised to release pig trial results later this week. The Duravest strategy encompasses three themes: (1) **rapid commercialization** of next-generation medical technologies by providing its portfolio of subsidiaries with financial, operational and scientific support, (2) **prioritization of safety** and (3) development of **convergent medical technologies** that span the traditional categories of biotechnology, pharmaceuticals, healthcare IT and medical devices.

####

Safe Harbor Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward-looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.